Cost-Utility of Sunitinib (SU) for Treatment of Advanced or Metastatic Pancreatic Neuroendocrine Tumors (pNET) in Scotland and Wales Abstract #538

Introduction: SU is an oral multitargeted tyrosine kinase inhibitor approved in Europe for advanced/metastatic well-differentiated pNET.
Aim(s): This study evaluated the cost-utility of SU + best supportive care (BSC) compared with placebo + BSC for health technology assessment submissions to Scotland and Wales (Jan and Mar 2011).
Materials and methods: A Markov model was developed to estimate quality-adjusted life-years (QALYs) and costs (£) of pNET treatment over lifetime, with three health states included: progression-free, post-progression and death. Transition probabilities (calculated using parametric survival modeling) and adverse event rates were based on the phase III pNET trial of SU, with extension-phase data included for overall survival (OS). BSC OS was adjusted for crossover with a rank-preserving structural failure time (RPSFT) model. Sensitivity analyses examined alternate survival assumptions and OS hazard ratios. Resource use was estimated by two UK pNET experts. A UK NHS perspective was adopted with 3.5% discounting.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Mr Adam Johns

To read results and conclusion, please login ...

Further abstracts you may be interested in

#127 Sunitinib for the treatment of advanced, progressive pancreatic neuroendocrine tumors
Introduction: Sunitinib is an oral, multitargeted tyrosine kinase inhibitor approved for use in advanced renal cell carcinoma and imatinib-resistant/intolerant gastrointestinal stromal tumors. Investigations of sunitinib in the RIP1-Tag2 mouse model and in phase I/II clinical trials provide evidence of antitumor activity against pancreatic neuroendocrine tumors (NET).
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Prof Eric Raymond
#136 Prevalence, severity and clinical outcome of malnutrition in gastroenteropancreatic neuroendocrine tumors
Introduction: Malnutrition is well-known to unfavorably influence clinical prognosis in patients (pts) with malignant diseases. However, in patients with neuroendocrine tumors (NET) prevalence and outcome of malnutrition are unknown although the gastroenteropancreatic system is most frequently involved.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Mr Sebastian Maasberg
#158 Progression-free survival (PFS) as a primary endpoint for clinical studies in advanced neuroendocrine tumors (NETs)
Introduction: Successfully testing new antitumor agents requires primary study endpoints that are clinically important, and also provide sufficient statistical power within a timeframe and population size that is feasible for the tumor type. Using overall survival (OS) as the primary endpoint in NET studies is challenging because of the low incidence (5.25/100,000 annually), disease heterogeneity, extended survival time (Yao 2008), and confounding effects of multiple therapies. These inherent aspects of NETs make OS an extremely difficult and challenging endpoint to evaluate clinical efficacy.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Simron Singh
Authors: Singh S, Law C,
#332 Impact of Baseline Ki-67 index and Other Baseline Characteristics on Outcome in a Study of Sunitinib (SU) for the Treatment of Advanced, Progressive Pancreatic Neuroendocrine Tumor (NET)
Introduction: Baseline Ki-67 index and other characteristics may influence outcome in patients (pts) with pancreatic NET; however, the value of Ki-67 and others have not been evaluated prospectively in trials.
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: Eric Raymond
#336 Overall Survival (OS) Analysis of Sunitinib (SU) After Adjustment for Crossover (CO) in Patients With Pancreatic Neuroendocrine Tumors (NET)
Introduction: A recent phase 3 trial of SU in pancreatic NET showed an improvement in progression-free survival (PFS) and OS. However, the OS benefit was confounded by early CO from placebo (PBO) to SU treatment.
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: Jack Ishak